| P50 | author | Georgia Beasley | Q42842714 |
| P2093 | author name string | Mark W Dewhirst | |
| | Michael A Davies | |
| | Yoshihiro Tokuhisa | |
| | Wanleng Deng | |
| | Douglas S Tyler | |
| | Ryan S Turley | |
| | Michael E Lidsky | |
| | Hiroaki Toshimitsu | |
| | Christina K Augustine | |
| | James C Padussis | |
| | Andrew Fontanella | |
| P2860 | cites work | Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 |
| | Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis | Q24608039 |
| | Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 |
| | RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 |
| | Cancer statistics, 2013 | Q27860762 |
| | N-cadherin acts upstream of VE-cadherin in controlling vascular morphogenesis | Q28505270 |
| | Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy | Q29547379 |
| | Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis | Q29614537 |
| | RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 |
| | Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial pressure. | Q30443689 |
| | Phosphorylation of VE-cadherin controls endothelial phenotypes via p120-catenin coupling and Rac1 activation | Q30497938 |
| | Differential expression of N-cadherin distinguishes a subset of metastasizing desmoplastic melanomas | Q30818087 |
| | A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. | Q34608282 |
| | Activating mutations of TOR (target of rapamycin). | Q35049778 |
| | E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors | Q35810162 |
| | Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma | Q36343055 |
| | Melanoma biology and new targeted therapy | Q36742015 |
| | N-cadherin as a therapeutic target in cancer | Q36764007 |
| | Pharmacotherapy of regional melanoma therapy | Q37650312 |
| | Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects | Q37732204 |
| | Regional treatment strategies for in-transit melanoma metastasis | Q37812815 |
| | Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy | Q39689330 |
| | Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide | Q39905603 |
| | RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway. | Q40318240 |
| | Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity | Q40333239 |
| | The human glutathione S-transferase P1 protein is phosphorylated and its metabolic function enhanced by the Ser/Thr protein kinases, cAMP-dependent protein kinase and protein kinase C, in glioblastoma cells. | Q40479888 |
| | Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors | Q40550209 |
| | Novel expression of N-cadherin elicits in vitro bladder cell invasion via the Akt signaling pathway. | Q40560244 |
| | Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 |
| | Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma | Q42723115 |
| | Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome | Q43496194 |
| | Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. | Q43675314 |
| | Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases | Q44185238 |
| | Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. | Q44260429 |
| | Modulation of resistance to regional chemotherapy in the extremity melanoma model | Q45010668 |
| | Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro | Q45249533 |
| | A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. | Q45917900 |
| | Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment | Q46593339 |
| | Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells | Q47324253 |
| | Shifts in cadherin profiles between human normal melanocytes and melanomas | Q47971517 |
| | IQGAP1 mediates VE-cadherin-based cell-cell contacts and VEGF signaling at adherence junctions linked to angiogenesis | Q53618817 |
| | Melanoma | Q56428909 |
| | Clinical and pharmacological phase I evaluation of ExherinTM (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours | Q62944928 |
| | Evidence for active transport of melphalan by two amino acid carriers in L5178Y lymphoblasts in vitro | Q67017574 |
| | Melphalan concentration dependent plasma protein binding in healthy humans and rats | Q69021388 |
| | Immunological detection of DNA damage caused by melphalan using monoclonal antibodies | Q69745638 |
| | Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy | Q80380578 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 368-377 | |
| P577 | publication date | 2015-02-01 | |
| P1433 | published in | Annals of Surgery | Q4767866 |
| P1476 | title | Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma | |
| P478 | volume | 261 | |